If your company plans to market a drug product in Latin American countries, are you aware of the CMC challenges and also opportunities in Latin America? In this article, originally published on Sept. 13, 2020, Redica Systems Senior GMP Quality Expert Jerry Chapman examines the overall drug approval process in this part of the world.

The Latin American region of the globe—which includes large countries such as Brazil, Mexico, Argentina, Columbia, and Peru—is undergoing a transformation marked by the stepwise harmonization of pharmaceutical regulations with international norms and standards. While it is a slow process and each country’s regulatory agency faces its own unique journey, progress is being made.

At the FDA/Xavier PharmaLink conference held virtually in March 2020, Merck CMC Director and Senior Scientist Tatiana Gaban—who has led Merck’s CMC Latin America team based in Sao Paulo—provided an in-depth look at the changing CMC regulatory landscape in Latin America.

Part I of this three-part article explores Gaban’s insights into drug product approval processes within the region, including challenges and opportunities. The two subsequent articles will provide more details on specific country requirements for Brazil, Mexico, Argentina, Columbia, and Peru.

She characterized Latin America as a region with “a very evolving regulatory landscape with highly active health authorities.” Activity is measured by the volume of draft/final regulations a regulatory body promulgates and its frequency of interactions with trade associations and the drug companies it regulates, the Merck director explained.

Harmonization and regulatory convergence in the region are primarily taking place in line with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). This occurs as national regulatory agencies become observers or members of ICH and adopt some of its guidelines.

Global versus Local Requirements

Although the agencies seek global harmonization, “they are struggling with the right balance of local versus global requirements,” Gaban said. While Brazil, Mexico, and Colombia are officially adopting the ICH guidelines, “there is a high demand for country-specific requirements.”

She characterized Latin America as a region with “a very evolving regulatory landscape

The governments rely on product approvals by reference regulators such as FDA and EMA to inform their decision-making but still carry strong sovereignty over regulatory processes. Even though Latin American health authorities are interested in knowing approval information that was submitted to the reference health authorities, on most occasions they require some level of CMC data for review by doctors within their country. 

The information that is required in addition to that submitted to reference health authorities Gaban terms “ancillary documents.”

“Country-specific CMC requirements demand substantial coordination from pharmaceutical companies both pre- and post-approval,” Gaban emphasized. “When we work in regional companies and we must plan files that are going to be released and filed across the globe, there is a lot of coordination that has to be done. The more varieties that you have in the regulatory requirements worldwide, the more difficult it is going to be to manage the information. Working with global filings can be particularly challenging.”

There are many ancillary documents requested for filings in many countries—for example, declarations and raw data. The list of required documents is extensive. The Common Technical Document (CTD) Module 3 is used as a source of information, but customization is happening at the country level. And there is still some specific work that occurs at the country level, such as translations and templates for local forms. 

“Brazil is the only country in Latin America that has published a guideline on ICH and forms related to the structure of the CTD,” Gaban said.

Gaban provided a table that shows “the number of ancillary documents that could be required for small molecule registration for some markets in Latin America, sometimes with extremely specific demands. This is an example from the company I work for, Merck. There are specific documents that are needed in addition to the core content that is used worldwide” (Figure 1).

Latin America Overview

FIGURE 1 | Overview of Ancillary Documents Needed for Small New Molecule Registration

Working with global filings can be particularly challenging

Approximately 48 ancillary documents are required in addition for Brazil, 23 for Mexico, 20 for Peru, 16 for Ecuador, and 13 for Argentina. 

“The number may vary, but it will be close to this,” Gaban explained.

Challenges and Opportunities

In summary, “when we think about the regulatory environment in Latin America, we think about regulatory convergence. We try to plan regulatory filings in advance using the principles of strategic and operational excellence,” Gaban said (Figure 2).

Challenges and Opportunities in Latin America

FIGURE 2 | Challenges and Opportunities in Latin America

“Regarding regulatory convergence, we have some challenges. Convergence demands strong efforts with policy and advocacy. Health Authorities are open for dialog but implementation may be challenging. We also have opportunities to streamline regulatory processes and decrease approval timelines, allowing products to patients quicker.”

She noted that when planning regulatory filings in advance, challenges include a fast-evolving regulatory environment and that requirements and Health Authority expectations may change along the way. Opportunities include anticipating critical hurdles and pre-submission meetings in some large markets such as Mexico and Brazil.

When discussing balancing risks and benefits, challenges include the amount of work demanded by Latin America for filing may put the region in a lower prioritization wave inside the company. There are also opportunities, however, in that it is a region with a big population and various unmet medical needs.

The challenges in strategic and operational excellence include having qualified regulatory resources and considerable efforts to manage all operational demands. Opportunities include the use of bundling or shared packages—for example, in Central America and the Caribbean—taking advantage of the same language in Spanish-speaking countries.

Part II will look at specific requirements for Brazil while Part III will review CMC requirements for Mexico, Argentina, Columbia, and Peru.

Get Your Arms Around the World with Redica Systems

Our regulatory surveillance can help ensure you never miss a signal when it comes to regulatory updates from the Latin American region. Below are recent regulatory updates from this region:

Providing the criteria for conducting relative bioavailability / bioequivalence (BD/BE) studies and pharmacokinetic studies (Brazil)

Cofepris announces new Platform for Self-Managed Procedures (Mexico)

Provision 5640/2022 on the request for authorization of in vivo bioequivalence studies carried out in the country (Argentina)

Log in to your Redica Systems account to access these regulatory documents. Don’t have a Redica Systems account? Contact us to see how our platform can help your team stay on top of ever-changing regulatory developments around the world.

Additional Global Regulatory Updates

How To Get Products Approved In Asia-Pacific Markets

Navigating Drug Approvals and Post-Approval Changes in the Asia-Pacific Region

An Inside Look at China’s Regulatory and Drug Approval Processes

UK’s MHRA Reinventing Itself as Sovereign Regulator

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Systems

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.